Skip to content
Clinical Trials – home

Medical University Of Vienna

Verified siteinfo

Austria Waehringer Guertel 18-20, Alsergrund, 1090 Vienna, Austria

  • 260 trials recruiting
  • Colitis ulcerative · Crohn's disease · Breast cancer
  • Adults and children

About Specializations

Medical University Of Vienna in Vienna, Austria specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Breast cancer, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

HER3‑Targeted Antibody‑Drug Conjugate Research

The division focuses on evaluating a novel HER3‑DXd in patients with advanced cancers that have spread to the central nervous system.

  • Intracranial objective response assessment
  • Overall survival analysis in leptomeningeal disease
  • HER3 expression as a therapeutic target

The studies are conducted at Medical University of Vienna with strong collaboration between academic investigators and commercial partners.

Central Nervous System Metastasis Trials

Clinical investigations address brain metastases arising from Metastatic Breast Cancer and Non‑Small Cell Lung Cancer, aiming to improve treatment outcomes inside the skull.

  • Use of Response Assessment in Neuro‑Oncology Brain Metastases (RANO‑BM) criteria
  • Evaluation of intracranial objective response rate
  • Multi‑cohort design to compare different tumor origins

Over 184 investigators contribute to these trials, reflecting the site’s extensive expertise in neuro‑oncology.

Leptomeningeal Carcinomatosis Studies

A dedicated cohort investigates patients with solid tumors and untreated leptomeningeal disease, testing whether the HER3‑conjugate can extend survival.

  • Assessment of three‑month overall survival
  • Safety monitoring in the spinal and cranial CSF compartments
  • Biomarker analysis of HER3 expression in leptomeningeal cells

The program highlights the department’s commitment to tackling rare and aggressive CNS complications of cancer.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Site location
Waehringer Guertel 18-20, Alsergrund1090 ViennaAustria
Recruiting now
260 trials
Conditions studied
378
Partner status
Verified site

More sites in ViennaAustria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

649 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Argenx
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.